Study of Topical Calcitriol in Children With Psoriasis - Full Text View

Study of Topical Calcitriol in Children With Psoriasis

This study has been completed.

Sponsors and Collaborators:	National Center for Research Resources (NCRR) Boston University
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00006275

Purpose

OBJECTIVES:

I. Determine the therapeutic efficacy and safety of topical calcitriol in children with psoriasis.

Condition	Intervention
Psoriasis	Drug: calcitriol

MedlinePlus related topics:

Psoriasis

Drug Information available for:

Calcitriol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	20
Study Start Date:	July 2000
Estimated Study Completion Date:	July 2000

Detailed Description:

PROTOCOL OUTLINE: Patients apply topical calcitriol in petrolatum on a psoriatic lesion daily. Patients also apply petrolatum without calcitriol to another psoriatic lesion daily.

Patients have both lesions photographed prior to therapy, monthly during therapy, and at the completion of therapy. Lesions are assessed weekly for 1 month and then every 2 weeks while on study. Blood samples are collected every 1 to 2 months and urine samples are collected every 2 weeks while on study.

Eligibility

Ages Eligible for Study:	4 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of psoriasis At least 2 lesions with area at least 30-50 cm2

--Prior/Concurrent Therapy--

No other concurrent therapy for psoriasis No concurrent calcium supplements greater than 1,000 mg/day No concurrent prednisone or other drugs affecting serum or urine calcium levels

--Patient Characteristics--

Renal: No high blood or urinary calcium levels

Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006275

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Boston University

Investigators


Study Chair:	Michael F. Holick	Boston University

More Information

Study ID Numbers:	199/15372, BUSM-90-106
First Received:	September 11, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00006275
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

dermatologic disorders

psoriasis

rare disease

Study placed in the following topic categories:

Skin Diseases

Psoriasis

Rare Diseases

Skin Diseases, Papulosquamous

Calcitriol

Additional relevant MeSH terms:

Membrane Transport Modulators

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Growth Substances

Vitamins

Calcium Channel Agonists

Physiological Effects of Drugs

Vasoconstrictor Agents

Bone Density Conservation Agents

Cardiovascular Agents

Micronutrients

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008